SiBone (NASDAQ:SIBN) Announces Quarterly Earnings Results

Key Points

• SiBone reported a quarterly earnings per share of ($0.14), which exceeded the analysts' consensus estimate of ($0.19) by $0.05.
• The company's stock price increased to $17.90 during trading, and it has a market capitalization of $762.81 million.
• Several hedge funds have recently adjusted their positions, with a significant 98.11% of the stock now owned by institutional investors.

SiBone (NASDAQ:SIBN - Get Free Report) announced its quarterly earnings results on Monday. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.05, Zacks reports. SiBone had a negative return on equity of 14.20% and a negative net margin of 12.83%. The business had revenue of $48.63 million during the quarter, compared to the consensus estimate of $48.12 million. SiBone updated its FY 2025 guidance to EPS.

SiBone Stock Down 1.8%

Shares of NASDAQ SIBN traded down $0.30 during mid-day trading on Friday, hitting $16.02. 85,613 shares of the stock traded hands, compared to its average volume of 431,432. The company has a debt-to-equity ratio of 0.21, a quick ratio of 7.26 and a current ratio of 8.38. SiBone has a 52 week low of $11.70 and a 52 week high of $20.05. The company has a market cap of $682.77 million, a price-to-earnings ratio of -28.63 and a beta of 0.91. The stock has a fifty day moving average price of $17.75 and a 200-day moving average price of $16.63.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on SIBN shares. Truist Financial increased their price objective on SiBone from $20.00 to $22.00 and gave the stock a "buy" rating in a report on Tuesday, May 6th. Needham & Company LLC reissued a "buy" rating and set a $24.00 price objective on shares of SiBone in a report on Tuesday, May 6th. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $25.00 price objective on shares of SiBone in a report on Tuesday.

Insider Buying and Selling at SiBone

In other SiBone news, insider Anthony J. Recupero sold 4,147 shares of SiBone stock in a transaction on Friday, May 16th. The stock was sold at an average price of $19.56, for a total transaction of $81,115.32. Following the completion of the transaction, the insider owned 282,015 shares in the company, valued at approximately $5,516,213.40. The trade was a 1.45% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Michael A. Pisetsky sold 3,459 shares of the business's stock in a transaction on Friday, May 16th. The stock was sold at an average price of $19.66, for a total value of $68,003.94. Following the completion of the transaction, the senior vice president owned 264,636 shares of the company's stock, valued at $5,202,743.76. This represents a 1.29% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 58,218 shares of company stock valued at $1,121,435 in the last ninety days. Corporate insiders own 4.00% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Goldman Sachs Group Inc. raised its stake in shares of SiBone by 28.4% in the first quarter. Goldman Sachs Group Inc. now owns 379,757 shares of the company's stock worth $5,328,000 after purchasing an additional 83,919 shares during the last quarter. Jane Street Group LLC purchased a new position in shares of SiBone in the first quarter worth $1,818,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of SiBone by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,426 shares of the company's stock worth $343,000 after purchasing an additional 1,053 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd purchased a new position in shares of SiBone in the first quarter worth $225,000. Hedge funds and other institutional investors own 98.11% of the company's stock.

SiBone Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.